Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Banna

Showing results (881-890 of 991) with videos related to

Pageof 100
Sort By:
Plos Neglected Tropical Diseases|May 13, 2022
Mucosal-Associated Invariant T (MAIT) cells are highly activated in duodenal tissue of humans with Vibrio cholerae O1 infection: A preliminary reportTaufiqur R Bhuiyan, M Arifur Rahman, Shubhanshi Trivedi, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Environmental Health Perspectives|April 4, 2024
Arsenic Exposure-Related Hypertension in Bangladesh and Reduced Circulating Nitric Oxide BioavailabilityMoriom Khatun, Nazmul Haque, Abu Eabrahim Siddique, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
Chemosphere|January 10, 2020
Association between chronic arsenic exposure and the characteristic features of asthmaAbu Eabrahim Siddique, Mizanur Rahman, Md Imam Hossain, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
Pageof 100

Showing results (881-890 of 991) with videos related to

Sort By:
Pageof 100
Plos Neglected Tropical Diseases|May 13, 2022
Mucosal-Associated Invariant T (MAIT) cells are highly activated in duodenal tissue of humans with Vibrio cholerae O1 infection: A preliminary reportTaufiqur R Bhuiyan, M Arifur Rahman, Shubhanshi Trivedi, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Environmental Health Perspectives|April 4, 2024
Arsenic Exposure-Related Hypertension in Bangladesh and Reduced Circulating Nitric Oxide BioavailabilityMoriom Khatun, Nazmul Haque, Abu Eabrahim Siddique, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
Chemosphere|January 10, 2020
Association between chronic arsenic exposure and the characteristic features of asthmaAbu Eabrahim Siddique, Mizanur Rahman, Md Imam Hossain, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
Pageof 100